| 2001 | 2002 | 2004 | 2006 | ||||
---|---|---|---|---|---|---|---|---|
 | Rufiji | KU | Rufiji | KU | Rufiji | KU | Rufiji | KU |
Sulphadoxine-pyrimethamine | (N = 74) | (N = 66) | (N = 87) | (N = 77) | (N = 66) | (N = 65) | (N = 57) | (N = 52) |
 Early treatment failure (ETF)1 | 0% | 5% | 6% | 0% | 11% | 5% | 4% | 13% |
 Late treatment failure |  |  |  |  |  |  |  |  |
  Late clinical failure (LCF)2 | 1% | 0% | 0% | 0% | 8% | 3% | 19% | 10% |
  Late parasitological failure (LPF)3 | 8% | 5% | 18% | 8% | 5% | 6% | 7% | 12% |
 Adequate Clinical Response (ACR) | 99% | 95% | 94% | 100% | 82% | 92% | 77% | 77% |
 Adequate Clinical and Parasitological  Response (ACPR)4at Day 14 | 91% | 91% | 76% | 92% | 77% | 86% | 70% | 65% |
Artesunate-sulphadoxine-pyrimethamine | (N = 67) | (N = 59) | (N = 86) | (N = 78) | (N = 72) | (N = 66) | (N = 58) | (N = 57) |
 Early treatment failure (ETF)1 | 0% | 0% | 5% | 0% | 0% | 0% | 0% | 0% |
 Late treatment failure |  |  |  |  |  |  |  |  |
  Late clinical failure (LCF)2 | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 7% |
  Late parasitological failure (LPF)3 | 0% | 3% | 9% | 4% | 3% | 0% | 2% | 4% |
 Adequate Clinical Response (ACR) | 100% | 100% | 95% | 100% | 100% | 100% | 95% | 93% |
 Adequate Clinical and Parasitological  Response (ACPR)4at Day 14 | 100% | 97% | 86% | 96% | 97% | 100% | 93% | 89% |